0.000455580865603662 -0.000860541635029187 5.06200961781367E-05 -0.00210984560870663 -0.0019741837509492 -0.00318906605922549 -0.00187294355859278 -0.00460642875221461
Sign Up Today X
Thanks for submitting the form.
Stockreport

UCB's Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights [Yahoo! Finance]

Incyte Corporation (INCY)  More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
EXTON, PA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- New research from Spherix Global Insights shows that the Hidradenitis Suppurativa treatment landscape is entering a period of accelerated change as dermatologists reassess biologic use based on real-world performance and ongoing unmet need. While therapeutic options have expanded, many patients with moderate-to-severe disease continue to experience suboptimal control, reinforcing demand for more effective and durable solutions. Dermatologists project a near-term rebalancing of the biologic market away from AbbVie's Humira and toward IL-17 therapies, with UCB's Bimzelx positioned as the primary share gainer. Use of Novartis' Cosentyx is expected to remain stable, supported by established familiarity and consistent performance perceptions. Reported patient outcomes increasingly favor Bimzelx over Humira and adalimumab biosimilars, contributing to growing confidence in IL-17s for higher-burden disease. Despite these shifts, unmet need rem [Read more]
IMPACT SNAPSHOT EVENT TIME: INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
INCY alerts
from News Quantified
INCY
NEWS
INCY
Earnings
INCY
Analyst Actions
INCY
SEC Filings
Stockreport

UCB's Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights [Yahoo! Finance]

Incyte Corporation  (INCY) 
More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
EXTON, PA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- New research from Spherix Global Insights shows that the Hidradenitis Suppurativa treatment landscape is entering a period of accelerated change as dermatologists reassess biologic use based on real-world performance and ongoing unmet need. While therapeutic options have expanded, many patients with moderate-to-severe disease continue to experience suboptimal control, reinforcing demand for more effective and durable solutions. Dermatologists project a near-term rebalancing of the biologic market away from AbbVie's Humira and toward IL-17 therapies, with UCB's Bimzelx positioned as the primary share gainer. Use of Novartis' Cosentyx is expected to remain stable, supported by established familiarity and consistent performance perceptions. Reported patient outcomes increasingly favor Bimzelx over Humira and adalimumab biosimilars, contributing to growing confidence in IL-17s for higher-burden disease. Despite these shifts, unmet need rem [Read more]
IMPACT SNAPSHOT
EVENT TIME:
INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS